Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 9, 2025

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

View original at finance.yahoo.com
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Teva expects an adjusted operating margin of 30% by 2027 through cost savings and continued growth of branded drugs

    80% confidence

  • Teva anticipates generating more than $5 billion in revenues from its branded products by 2030

    80% confidence

  • Teva raised its 2025 Austedo sales expectations following IRA pricing negotiations conclusion

    80% confidence

  • Teva expects Uzedy total sales to be between $190 million and $200 million in 2025

    80% confidence

  • The outcome of the IRA pricing negotiations for Austedo went as expected

    80% confidence

  • Teva is a Hold stock with Zacks Rank #3

    80% confidence

  • Teva expects to launch Austedo in European markets in 2026

    80% confidence

  • Teva aims to double its global biosimilars sales by 2027

    80% confidence

  • CMS is expected to formally announce the agreement on a maximum fair price for Austedo in November 2025

    80% confidence

  • Austedo sales expected to exceed $3 billion by 2030

    80% confidence

  • Teva expects to file a new drug application for olanzapine before the year ends

    80% confidence

  • Austedo annual revenues expected to be more than $2.5 billion by 2027

    80% confidence

  • Teva expects five additional biosimilar launches by 2027

    80% confidence

  • In 2025, Teva expects its generics business to be flat to up in low single digits in constant currency terms

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play — Source | Via News | ViaNews Market